Atlas Trials

An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Clinical trial NCT00338416 · COMPLETED

Trial details

NCT number
NCT00338416
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
CancerAnemia
Start date
2003-03-01
Enrollment
115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.